Signios Bio and Illumina Announce Grant to Maximize Discovery Power with Industry’s Largest NGS-Based Proteomics Panel
Signios Biosciences (“Signios Bio”), a science-first biotechnology company leading in multiomics and AI-powered bioinformatics, in collaboration with Illumina, announced today an Illumina-sponsored grant for Early Access to Illumina Protein Prep 9.5K™. Powered by SOMAmer® technology, this next-generation sequencing (NGS)-based platform enables comprehensive proteomic profiling of plasma and serum.
Signios Bio Launches with AI-Driven Bioinformatics and Advanced Multiomics Platform to Power the Future of Precision Medicine and Drug Discovery
Signios Biosciences ("Signios Bio"), a science-first biotechnology company at the forefront of multiomics and AI-powered bioinformatics, today announced its rebranding from its previous identity as the US based research division of MedGenome Inc. This milestone marks a new era, better positioning the brand in the US on its mission of long-term partnership with researchers to accelerate precision medicine and drug discovery.
